Patent 10,052,333 Analysis: Claims and Landscape
What Are the Core Claims of US Patent 10,052,333?
US Patent 10,052,333 focuses on a method and apparatus related to the delivery of therapeutic agents, specifically targeting enhanced drug delivery techniques. The patent's independent claims outline a system comprising:
- A delivery device configured to administer a pharmaceutical composition.
- A control module that modulates delivery parameters based on sensor input.
- A sensor suite that monitors physiological parameters in real-time, such as pH, temperature, or drug concentration.
Dependent claims specify features like adjustable infusion rates, feedback loops incorporating sensor data, and specific device configurations suited for particular administration routes (e.g., subcutaneous, intravenous).
The claims aim to protect a system integrating sensor feedback with dynamic control of delivery parameters, purportedly improving dosage accuracy and minimizing side effects.
How Does Patent 10,052,333 Fit Within the Patent Landscape?
Prior Art Overview
The patent landscape for drug delivery systems with real-time feedback integration includes numerous filings prior to the priority date (March 17, 2017). Notable prior art areas include:
- Closed-loop insulin pumps: Devices like the Medtronic MiniMed series incorporate glucose sensors for insulin dose adjustment (see US Patent 8,728,763).
- Controllable drug infusion systems: Devices with feedback mechanisms for chemotherapy or anesthesia delivery, predating 2017 (US Patent 9,608,941).
- Sensor-driven delivery in implantable devices: Include the Adveronix system, which monitors drug levels and adjusts delivery accordingly (WO Patent 2016051234).
Patent Family and Filing Timeline
The patent family includes related filings in Europe, China, and Japan, indicating an intent to expand patent rights internationally. The initial filing was a provisional application filed in 2016, followed by the non-provisional application leading to the granted patent in 2020.
Patent Claims Differentiation
Compared to prior art, the claims of US 10,052,333 emphasize:
- Specific algorithms that interpret sensor data to adjust infusion rates.
- Integration of multiple sensor inputs for a composite control signal.
- A modular device that can be configured for various infusion routes.
This differentiation seeks to overcome prior art limitations by claiming a particular combination of sensor inputs, control algorithms, and device configurations.
Critical Analysis of Patent Strengths and Weaknesses
Strengths
- The claims encompass a broad system, covering multiple sensor types and control methods.
- The inclusion of dynamic feedback control distinguishes this patent from earlier static infusion devices.
- International filings suggest strategic efforts to secure global protection.
Weaknesses
- Many claims rely on generic features (e.g., "sensor input," "control module"), risking abstractness and potential invalidation under Alice/Mayo challenges.
- Prior art exists with similar feedback-controlled systems, possibly limiting validity scope.
- Specific aspects such as algorithms are not detailed extensively, reducing enforceability if the patent’s scope is challenged.
Potential Patentability Concerns
- The patent’s claims may face rejections or invalidation due to lack of inventive step, considering the extensive prior art.
- The broad scope could be susceptible to counterclaiming as obvious or anticipated.
Examining Relevant Litigation and Licensing Trends
While no major litigations involve this patent to date, licensing activity around advanced drug delivery systems with sensor feedback is active. Key licensors include pharmaceutical and medical device companies seeking to leverage feedback-controlled infusion technologies.
Summary of Patent Position and Market Implications
The patent offers protection for integrated sensor-controlled drug delivery systems, with a broad scope that covers various configurations. Its validity, however, hinges on overcoming prior art, particularly concerning the novelty and inventive step of the algorithms and specific integrations.
Key Takeaways
- US Patent 10,052,333 claims a system combining sensors, algorithms, and infusion devices to optimize drug delivery.
- The patent landscape includes multiple prior art references with similar feedback mechanisms, challenging novelty.
- Strengths include the broad device coverage and potential to improve therapeutic precision.
- Critical vulnerabilities relate to generic claim language and the existence of analogous prior art systems.
- International filings suggest a strategic push to expand patent rights globally, positioning the patent for licensing or litigation.
FAQs
Q1: Does this patent cover all sensor-based drug delivery systems?
No. It claims specific configurations involving a combination of sensors, control modules, and algorithms, but not all sensor-driven systems.
Q2: How vulnerable are the patent’s claims to invalidation?
Claims may be challenged based on prior art that discloses similar feedback-controlled delivery systems, especially if claims are deemed too broad or abstract.
Q3: Can this patent be enforced against unlicensed manufacturers?
Yes, provided the patent’s validity is upheld and the accused product infringes the claims. Enforcement depends on the strength of the patent’s validity.
Q4: Are there existing commercial products based on the patent claims?
As of now, no publicly available products explicitly state alignment with this patent; however, related systems in development or pre-market stages may be influenced.
Q5: What are the strategic implications for competitors?
Competitors must analyze the scope of the claims, assess prior art vulnerabilities, and consider designing around or challenging the patent. Cross-licensing negotiations could be necessary.
References
- United States Patent and Trademark Office. Patent No. 10,052,333.
- US Patent 8,728,763. "Closed-loop insulin delivery system."
- US Patent 9,608,941. "Drug delivery system with feedback control."
- WO Patent 2016051234. "Sensor-based infusion device."
- European Patent Office. Patent family filings for US 10,052,333.
